NEJM: LY-CoV555 combined with Redsyway cannot shorten the recovery period for hospitalized patients with neocyctic pneumonia

The antiviral drug Redsivir can reduce the recovery time of patients hospitalized for coronavirus disease (Covid-19) in 2019, while dexamisong can reduce patient mortality, but there is still an urgent need for more effective new coronary pneumonia drug treatment.
Ly-COV555 is a monoclonal mediated antibody, and in a study involving outpatients with coronary pneumonia, Ly-COV555 reduced viral load and the risk of hospitalization or emergency care.
researchers recently examined its effects on Covid-19 inpatients.
patients hospitalized with new coronary pneumonia without organ failure participated in the study and were randomly treated with LY-CoV555 or a placebo based on high-quality supportive treatments, including redsiver, oxygen absorption, and glucoticoids.
dose of LY-CoV555 is 7000 mg, administered in a single intravenous dose, and is completed within 1 hour.
end of the study was a sustained recovery within 90 days.
314 patients were studied, including 163 in the LY-CoV555 group and 151 in the placebo group, with an average symptom recovery period of 7 days.
day, 81 patients (50%) in the LY-CoV555 group and 81 patients (54%) in the placebo group had significantly improved their breathing and lung outcomes.
in seven clinical improvement assessments, LY-CoV555 had an optimal ratio of 0.85 compared to placebo.
results were similar (19% vs. 14%) in safety endpoint assessments that included deaths, serious adverse events, and 3-4 adverse events over a five-day period.
the continuous recovery rate difference between the two groups over a 90-day day (rr=1.06).
study concluded that the combined treatment of LY-CoV555 and Redsiway could not speed up the recovery time of patients hospitalized with neocyctic pneumonia.
。